First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
@article{TLCR78911, author = {Wenjie Liu and Gengwei Huo and Mengjie Li and Peng Chen}, title = {First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis}, journal = {Translational Lung Cancer Research}, volume = {12}, number = {9}, year = {2023}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/78911} }